Altered fractionation schedules in radiation treatment: a review.
暂无分享,去创建一个
T. Dilling | R. Shridhar | C. Correa | J. Caudell | A. Trotti | R. Wilder | K. Ahmed | N. Rao | Nikhil Rao
[1] venlig hilsen,et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck : DAHANCA 6 and 7 randomised controlled trial , 2016 .
[2] Geoffrey G. Zhang,et al. Clinical Investigation : Thoracic Cancer Study of 201 Non-Small Cell Lung Cancer Patients Given Stereotactic Ablative Radiation Therapy Shows Local Control Dependence on Dose Calculation Algorithm , 2022 .
[3] T. Iuchi,et al. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. , 2014, International journal of radiation oncology, biology, physics.
[4] M. Steinberg,et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. , 2013, International journal of radiation oncology, biology, physics.
[5] R. Stoyanova,et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Anurag K. Singh,et al. Radiation Therapy Oncology Group (RTOG) Protocol 0915: A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer , 2013 .
[7] Joanne S Haviland,et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. , 2013, The Lancet. Oncology.
[8] Ravi Shridhar,et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. , 2013, International journal of radiation oncology, biology, physics.
[9] M. Santoro,et al. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years , 2013, Radiation oncology.
[10] Wei Xu,et al. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Christopher U. Jones,et al. RTOG 90-03: Final Report , 2012 .
[12] Allen Waziri,et al. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. , 2012, International journal of radiation oncology, biology, physics.
[13] Didier Frappaz,et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[14] R. Fisher,et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. , 2012, The Lancet. Oncology.
[15] Suresh Senan,et al. Curative treatment of Stage I non-small-cell lung cancer in patients with severe COPD: stereotactic radiotherapy outcomes and systematic review. , 2012, International journal of radiation oncology, biology, physics.
[16] V. Grégoire,et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. , 2012, The Lancet. Oncology.
[17] K. Horst,et al. Fractionation for whole breast irradiation: An American Society for Radiation Oncology (ASTRO) evidence-based guideline , 2012 .
[18] J. Stockman. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer , 2012 .
[19] W. Hohenberger,et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Senan,et al. Outcomes of Stereotactic Ablative Radiotherapy for Centrally Located Early-Stage Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] J. Fowler,et al. Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. , 2011, International journal of radiation oncology, biology, physics.
[22] E. Kasper,et al. Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases. , 2011, International journal of radiation oncology, biology, physics.
[23] Benjamin Movsas,et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. , 2011, Journal of the National Cancer Institute.
[24] L. Specht,et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[25] V. Budach,et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[26] Hein Putter,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.
[27] D. Kuban,et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? , 2008, International journal of radiation oncology, biology, physics.
[28] M. Gapany. Mature results of a randomized trial of accelerated hyperfractionated versus conventional radiotherapy in head-and-neck cancer , 2011 .
[29] K. Ang,et al. Hyperfractionated or accelerated radiotherapy for head and neck cancer. , 2010 .
[30] N. Neerchal,et al. Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients , 2010, Journal of Gastrointestinal Surgery.
[31] C. Grau,et al. Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. , 2010, The Lancet. Oncology.
[32] R. Weber,et al. A Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination with Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Report of Efficacy and Toxicity , 2010 .
[33] Anthony Fyles,et al. Long-term results of hypofractionated radiation therapy for breast cancer. , 2010, The New England journal of medicine.
[34] Andrea Bezjak,et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.
[35] D. Heron,et al. Fractionated Stereotactic Body Radiation Therapy in the Treatment of Previously-Irradiated Recurrent Head and Neck Carcinoma: Updated Report of the University of Pittsburgh Experience , 2009, American journal of clinical oncology.
[36] Tarek Mekhail,et al. A Comparison of Two Stereotactic Body Radiation Fractionation Schedules for Medically Inoperable Stage I Non-small Cell Lung Cancer: The Cleveland Clinic Experience , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[37] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[38] R. Arriagada,et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. , 2009, The Lancet. Oncology.
[39] A. Zietman,et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. , 2009, Urology.
[40] Yun Yen,et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.
[41] Jeffrey E. Lee,et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. , 2009, International journal of radiation oncology, biology, physics.
[42] J. Monson,et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial , 2009, The Lancet.
[43] M. Celeste Simon,et al. The impact of O2 availability on human cancer , 2008, Nature Reviews Cancer.
[44] J. Yarnold,et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet. Oncology.
[45] J R Yarnold,et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial , 2008, The Lancet.
[46] E. Glatstein,et al. Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer , 2008 .
[47] P. Warde,et al. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[48] M. Parmar,et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. , 2007, The Lancet. Oncology.
[49] W. Mendenhall,et al. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. , 2006, International journal of radiation oncology, biology, physics.
[50] Paul Schellhammer,et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.
[51] J. Bourhis,et al. Phase III randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer: a GORTEC trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Joos V Lebesque,et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] H. Yamazaki,et al. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. , 2006, International journal of radiation oncology, biology, physics.
[54] A. Lippold,et al. Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. , 2005, Journal of the American Academy of Dermatology.
[55] Sharon A. Spencer,et al. Long Term Outcomes of RTOG 90–03: A Comparison of Hyperfractionation and Two Variants of Accelerated Fractionation to Standard Fractionation Radiotherapy for Head and Neck Squamous Cell Carcinoma , 2005 .
[56] D. Brizel,et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[57] Daniel W. Miller,et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. , 2005, JAMA.
[58] L. Påhlman,et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] P. Wust,et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[60] W. J. Morris,et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] K. Rufibach,et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] Rainer Fietkau,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.
[63] T. Pawlik,et al. Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.
[64] E. Bruera,et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[65] Stephanie Frost,et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. , 2003, Chest.
[66] John D. Roberts,et al. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. , 2003, International journal of radiation oncology, biology, physics.
[67] Cai Grau,et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial , 2003, The Lancet.
[68] G. Noël,et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer , 2002 .
[69] D. Hedley,et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] A. Serafin,et al. A multicentre randomized/controlled trial of a conventional versus modestly accelerated radiotherapy in the laryngeal cancer: influence of a 1 week shortening overall time. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[71] Rieken,et al. [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer]. , 2001, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].
[72] J. Meza,et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. , 2001, International journal of radiation oncology, biology, physics.
[73] L. Peters,et al. A randomised trial of accelerated and conventional radiotherapy for stage III and IV squamous carcinoma of the head and neck: a Trans-Tasman Radiation Oncology Group Study , 2001 .
[74] B. Jeremic,et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] W. Curran,et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. , 2001, Chest.
[76] J. Naude,et al. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancers. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[77] W. Curran,et al. Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer : Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group , 2000 .
[78] W. Mendenhall,et al. Radiotherapy alone for clinical T4 skin carcinoma of the head and neck with surgery reserved for salvage , 2000 .
[79] A Harvey,et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering committee. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[80] D. Joseph,et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[81] R. Komaki,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.
[82] Jay S. Cooper,et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003 , 1999 .
[83] A. Huang,et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. , 1998, The New England journal of medicine.
[84] A. Aupérin,et al. Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. , 1997, British Journal of Cancer.
[85] T. Walsh,et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. , 1996, The New England journal of medicine.
[86] D. Nelson,et al. Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas: Radiation therapy oncology group study 83‐02 , 1996, Cancer.
[87] I. Näslund,et al. Hyperfractionated radiotherapy of bladder cancer. A ten-year follow-up of a randomized clinical trial. , 1994, Acta oncologica.
[88] K. Stelzer,et al. A randomized prospective trial of radiation therapy for AIDS-associated Kaposi's sarcoma. , 1993, International journal of radiation oncology, biology, physics.
[89] S Schraub,et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[90] J. Cooper,et al. Fraction size in external beam radiation therapy in the treatment of melanoma. , 1991, International journal of radiation oncology, biology, physics.
[91] L. Souhami,et al. Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. , 1991, International journal of radiation oncology, biology, physics.
[92] C. Perez,et al. External irradiation of epithelial skin cancer. , 1990, International journal of radiation oncology, biology, physics.
[93] J. Lozier,et al. Radiation therapy of skin carcinomas: results of a hypofractionated irradiation schedule in 675 cases followed more than 2 years. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[94] B. Nilsson,et al. Irradiation therapy with multiple small fractions per day in urinary bladder cancer. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[95] T. Kinsella,et al. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. , 1983, Cancer research.
[96] R. Hatlevoll,et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the scandinavian glioblastoma study group , 1981, Cancer.
[97] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[98] H. Withers,et al. Four R's of radiotherapy , 1975 .
[99] R. Lindberg,et al. Radiation therapy administered under conditions of tourniquet-induced local tissue hypoxia. , 1968, The American journal of roentgenology, radium therapy, and nuclear medicine.